Cargando…

Optimizing tylosin dosage for co-infection of Actinobacillus pleuropneumoniae and Pasteurella multocida in pigs using pharmacokinetic/pharmacodynamic modeling

Formulating a therapeutic strategy that can effectively combat concurrent infections of Actinobacillus pleuropneumoniae (A. pleuropneumoniae) and Pasteurella multocida (P. multocida) can be challenging. This study aimed to 1) establish minimum inhibitory concentration (MIC), minimum bactericidal con...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Eon-Bee, Abbas, Muhammad Aleem, Park, Jonghyun, Tassew, Dereje D., Park, Seung-Chun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10556534/ https://www.ncbi.nlm.nih.gov/pubmed/37808183 http://dx.doi.org/10.3389/fphar.2023.1258403

Ejemplares similares

Prediction of marbofloxacin dosage for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida by pharmacokinetic/pharmacodynamic modelling
por: Dorey, Lucy, et al.
Publicado: (2017)

Pharmacokinetic/pharmacodynamic integration and modelling of florfenicol for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida
por: Dorey, Lucy, et al.
Publicado: (2017)

Pharmacokinetic/pharmacodynamic integration and modelling of oxytetracycline for the porcine pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida
por: Dorey, L., et al.
Publicado: (2017)

What is the true in vitro potency of oxytetracycline for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida?
por: Dorey, L., et al.
Publicado: (2017)

Serological patterns of Actinobacillus pleuropneumoniae, Mycoplasma hyopneumoniae, Pasteurella multocida and Streptococcus suis in pig herds affected by pleuritis
por: Wallgren, Per, et al.
Publicado: (2016)

Susceptibility of Actinobacillus pleuropneumoniae, Pasteurella multocida and Streptococcus suis Isolated from Pigs in Hungary between 2018 and 2021
por: Somogyi, Zoltán, et al.
Publicado: (2023)

Pharmacokinetic and Pharmacodynamic Evaluation of Marbofloxacin in Pig against Korean Local Isolates of Actinobacillus pleuropneumoniae
por: Hossain, Md. Akil, et al.
Publicado: (2017)

In vitro and in vivo Synergistic Effects of Florfenicol and Thiamphenicol in Combination Against Swine Actinobacillus pleuropneumoniae and Pasteurella multocida
por: Rattanapanadda, Porjai, et al.
Publicado: (2019)

Antimicrobial Resistance of Actinobacillus pleuropneumoniae, Streptococcus suis, and Pasteurella multocida Isolated from Romanian Swine Farms
por: Siteavu, Madalina Iulia, et al.
Publicado: (2023)

Optimization and Validation of Dosage Regimen for Ceftiofur against Pasteurella multocida in Swine by Physiological Based Pharmacokinetic–Pharmacodynamic Model
por: Mi, Kun, et al.
Publicado: (2022)

Characterization of small plasmids carrying florfenicol resistance gene floR in Actinobacillus pleuropneumoniae and Pasteurella multocida isolates from swine in China
por: Yao, Xiaohui, et al.
Publicado: (2023)

Pharmacokinetic-pharmacodynamic modeling of tylosin against Streptococcus suis in pigs
por: Huang, Lingli, et al.
Publicado: (2018)

Murine Thigh Microdialysis to Evaluate the Pharmacokinetic/Pharmacodynamic Integration of Cefquinome Against Actinobacillus pleuropneumoniae
por: Zhang, Longfei, et al.
Publicado: (2020)

Immunohistochemical and molecular analysis of Pasteurella multocida in a rabbit with suppurative pleuropneumonia
por: UENOYAMA, Kei, et al.
Publicado: (2019)

Pharmacokinetic/Pharmacodynamic Integration to Evaluate the Changes in Susceptibility of Actinobacillus pleuropneumoniae After Repeated Administration of Danofloxacin
por: Zhang, Longfei, et al.
Publicado: (2018)

Pharmacokinetics/pharmacodynamics of marbofloxacin in a Pasteurella multocida serious murine lung infection model
por: Qu, Ying, et al.
Publicado: (2015)

Pharmacokinetics and Pharmacodynamics of Tildipirosin Against Pasteurella multocida in a Murine Lung Infection Model
por: Zeng, Dongping, et al.
Publicado: (2018)

Pharmacokinetics and Pharmacodynamics of Gamithromycin Treatment of Pasteurella multocida in a Murine Lung Infection Model
por: Yang, Qingwen, et al.
Publicado: (2019)

Pharmacokinetic/Pharmacodynamic Relationships of Tulathromycin Against Actinobacillus pleuropneumoniae in a Porcine Tissue Cage Infection Model
por: Yao, Lihua, et al.
Publicado: (2022)

Pharmacokinetic/Pharmacodynamic Modeling of Tulathromycin against Pasteurella multocida in a Porcine Tissue Cage Model
por: Zhou, Qiaoyi, et al.
Publicado: (2017)

Pharmacokinetic/pharmacodynamic integration of tilmicosin against Pasteurella multocida in a piglet tissue cage model
por: Chen, Yuqin, et al.
Publicado: (2023)

Mutant prevention and minimum inhibitory concentration drug values for enrofloxacin, ceftiofur, florfenicol, tilmicosin and tulathromycin tested against swine pathogens Actinobacillus pleuropneumoniae, Pasteurella multocida and Streptococcus suis
por: Blondeau, Joseph M., et al.
Publicado: (2019)

Histopathological lesions of Actinobacillus pleuropneumoniae serotype 8 in infected pigs
por: Papatsiros, Vasileios Georgios, et al.
Publicado: (2023)

Pasteurella multocida bacterial meningitis caused by contact with pigs
por: López, C., et al.
Publicado: (2013)

Pasteurella multocida Epiglottitis
por: Moyko, Andrey, et al.
Publicado: (2017)

Characterisation of Pasteurella multocida isolates from pigs with pneumonia in Korea
por: Kim, Jongho, et al.
Publicado: (2019)

Integrated pharmacokinetic–Pharmacodynamic (PK/PD) model to evaluate the in vivo antimicrobial activity of Marbofloxacin against Pasteurella multocida in piglets
por: Zeng, Qing Lin, et al.
Publicado: (2017)

In vivo Pharmacokinetic and Pharmacodynamic (PK/PD) Modeling and Establishment of the PK/PD Cutoff of Florfenicol Against Pasteurella multocida in Ducks
por: Xiao, Xia, et al.
Publicado: (2021)

Evaluating a tylosin dosage regimen for treatment of Staphylococcus delphini infection in mink (Neovison vison): a pharmacokinetic-pharmacodynamic approach
por: Ronaghinia, Amir Atabak, et al.
Publicado: (2021)

Profiling microRNAs in lung tissue from pigs infected with Actinobacillus pleuropneumoniae
por: Podolska, Agnieszka, et al.
Publicado: (2012)

Association between transmission rate and disease severity for Actinobacillus pleuropneumoniae infection in pigs
por: Tobias, Tijs J, et al.
Publicado: (2013)

Concurrent host-pathogen gene expression in the lungs of pigs challenged with Actinobacillus pleuropneumoniae
por: Brogaard, Louise, et al.
Publicado: (2015)

Host-pathogen interplay at primary infection sites in pigs challenged with Actinobacillus pleuropneumoniae
por: Sassu, Elena L., et al.
Publicado: (2017)

Infective Exacerbation of Pasteurella multocida
por: Hamada, Mayumi, et al.
Publicado: (2016)

Infantile Pasteurella multocida meningitis
por: Nauseef, Jones T., et al.
Publicado: (2016)

Endocarditis caused by Pasteurella multocida
por: Al Ghonaim, Mohammed A., et al.
Publicado: (2006)

Pasteurella Multocida Infection in Humans
por: Piorunek, Marcin, et al.
Publicado: (2023)

Development of an Online Tool for Pasteurella multocida Genotyping and Genotypes of Pasteurella multocida From Different Hosts
por: Peng, Zhong, et al.
Publicado: (2021)

Actinobacillus pleuropneumoniae Interaction With Swine Endothelial Cells
por: Plasencia-Muñoz, Berenice, et al.
Publicado: (2020)

Novel DNA Markers for Identification of Actinobacillus pleuropneumoniae
por: Srijuntongsiri, Gun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_akeg3mnuo6j7a0vj88hi7ih4jg